Edwards Lifesciences (EW) Tops Q2 EPS by 20c; Raises Outlook

Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $1.08, $0.20 better than the analyst estimate of $0.88. Revenue for the quarter came in at $842 million versus the consensus estimate of $840.06 million.

GUIDANCE:

Edwards Lifesciences sees FY2017 EPS of $3.65-$3.85, versus the consensus of $3.53.

Edwards Lifesciences sees Q3 2017 EPS of $0.80-$0.90, versus the consensus of $0.83.

Outlook

For the full year 2017, given the strong first half results, the company\'s full year sales estimate is now at the high end of its previous $3.2 to $3.4 billion guidance. The company is also raising its estimate for 2017 adjusted earnings per share to $3.65 to $3.85, from $3.43 to $3.55.

For the third quarter of 2017, the company projects underlying sales, adjusting for the impact of Germany stocking sales consumption, to be between $810 and $850 million, and adjusted earnings per share of $0.80 to $0.90.

\As we reflect on our first half results, we are very pleased with the performance achieved across all of our product lines and believe our future remains bright," said Mussallem. "We are confident our valuable innovations will result in a continued strong outlook as we deliver important solutions for the patients we serve.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Hermès can regain momentum despite China weakness, Jefferies says
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target